Feature | Contrast Media | June 04, 2015

First U.S. Lumason Echocardiography Imaging Procedure Performed

Contrast agent indicated to opacify left ventricular chamber in suboptimal echocardiograms

Bracco, Lumason, first U.S. echocardiography procedure, Morristown

June 4, 2015 - Bracco Imaging announced that the first echocardiography imaging procedure with Lumason was performed in May at Morristown Medical Center, part of the Atlantic Health System, in New Jersey. This is the first administration after the development of the agent (sulfur hexafluoride lipid-type A microspheres) in the United States and approval by the U.S. Food and Drug Administration. The announcement was made through Bracco Imaging's affiliate Bracco Diagnostics Inc.

 "We're thrilled to be the first medical center to use Lumason in adults with suboptimal echocardiograms," said Linda Gillam, M.D., MPH, FASE, chair of the Gagnon Cardiovascular Institute at Morristown Medical Center. "Now we have an additional option when performing contrast enhanced ultrasound."

Lumason, internationally known as SonoVue in 40 countries, is an ultrasound contrast agent made up of gas-filled microbubbles (or microspheres) that reflect the sound waves to enhance the image.

Lumason has been approved by the FDA for use in adults with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

The agent is supplied as a three-part kit. Each kit contains a Lumason vial containing 25 mg of lipid-type A lyophilized powder and 60.7 mg sulfur hexafluoride headspace, a prefilled syringe containing 5 mL of sodium chloride 0.9 percent injection, USP (Diluent), and a Mini-Spike.

For more information: www.braccoimaging.com

Related Content

Philips Introduces Technology Maximizer Program for Imaging Equipment Upgrades
Technology | Imaging | January 17, 2018
January 17, 2018 — Philips recently announced the launch of Technology Maximizer, a cross-modality program designed t
New Vascular Ultrasound Registry Looks to Enhance Patient Care
News | Cardiovascular Ultrasound | January 17, 2018
The Society for Vascular Ultrasound (SVU), the Society for Vascular Surgery (SVS) and Medstreaming-M2S announced the...
Study Finds No Evidence that Gadolinium Causes Neurologic Harm

MR images through, A, C, E, basal ganglia and, B, D, F, posterior fossa at level of dentate nucleus. Images are shown for, A, B, control group patient 4, and the, C, D, first and, E, F, last examinations performed in contrast group patient 13. Regions of interest used in quantification of signal intensity are shown as dashed lines for globus pallidus (green), thalamus (blue), dentate nucleus (yellow), and pons (red).

News | Contrast Media | January 11, 2018
January 11, 2018 — There is no evidence that accumulation in the brain of the element gadolinium speeds cognitive dec
Sponsored Content | Videos | Ultrasound Imaging | January 11, 2018
Mindray recently featured a new upgrade for its premium Resona 7 ultrasound system at the Radiological Society of North...
Male Triathletes May Be Putting Their Heart Health at Risk
News | Cardiac Imaging | January 09, 2018
Competitive male triathletes face a higher risk of a potentially harmful heart condition called myocardial fibrosis,...
New International Report Provides Comprehensive Guide to Imaging in Chagas Heart Disease
News | Cardiovascular Ultrasound | January 03, 2018
Chagas disease (ChD), an infectious parasitic disease transmitted primarily by triatomine insects, has become a...
Toshiba Medical Introduces New Entry-Level Aplio i600 Ultrasound Platform
News | Ultrasound Imaging | December 21, 2017
Toshiba Medical, a Canon Group company, showcased the Aplio i600, the newest addition to the premium Aplio i-series...
Bay Labs Completes $5.5 Million Series A Financing for AI-Driven Ultrasound
News | Cardiovascular Ultrasound | December 21, 2017
December 21, 2017 — Bay Labs, a medical technology company applying...
Overlay Init